Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

NCT05577754 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Dijon as lead sponsor.

NCT NCT05577754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)
Lead sponsor
Centre Hospitalier Universitaire Dijon
Phase
Phase 2
Overall status
Recruiting
Start date
November 28, 2022
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

megalencephaly-capillary malformation polymicrogyria syndrome (mcap)